GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » Piotroski F-Score

MusclePharm (MusclePharm) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MusclePharm Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MusclePharm has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for MusclePharm's Piotroski F-Score or its related term are showing as below:


MusclePharm Piotroski F-Score Historical Data

The historical data trend for MusclePharm's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MusclePharm Piotroski F-Score Chart

MusclePharm Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 2.00 6.00 2.00

MusclePharm Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 3.00 2.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Net Income was -2.251 + -3.933 + -6.776 + -6.301 = $-19.26 Mil.
Cash Flow from Operations was -0.997 + -1.567 + -5.576 + -3.582 = $-11.72 Mil.
Revenue was 14.908 + 11.971 + 10.042 + 13.101 = $50.02 Mil.
Gross Profit was 2.18 + 0.029 + -0.527 + 1.509 = $3.19 Mil.
Average Total Assets from the begining of this year (Mar21)
to the end of this year (Mar22) was
(9.949 + 10.94 + 11.311 + 11.21 + 11.977) / 5 = $11.0774 Mil.
Total Assets at the begining of this year (Mar21) was $9.95 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $11.84 Mil.
Total Current Liabilities was $48.17 Mil.
Net Income was -0.253 + 0.678 + 2.82 + 0.094 = $3.34 Mil.

Revenue was 16.993 + 16.085 + 15.131 + 13.121 = $61.33 Mil.
Gross Profit was 4.984 + 5.012 + 4.804 + 3.689 = $18.49 Mil.
Average Total Assets from the begining of last year (Mar20)
to the end of last year (Mar21) was
(14.795 + 13.861 + 10.217 + 13.002 + 9.949) / 5 = $12.3648 Mil.
Total Assets at the begining of last year (Mar20) was $14.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.23 Mil.
Total Current Assets was $8.98 Mil.
Total Current Liabilities was $29.51 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MusclePharm's current Net Income (TTM) was -19.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MusclePharm's current Cash Flow from Operations (TTM) was -11.72. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar21)
=-19.261/9.949
=-1.93597346

ROA (Last Year)=Net Income/Total Assets (Mar20)
=3.339/14.795
=0.22568435

MusclePharm's return on assets of this year was -1.93597346. MusclePharm's return on assets of last year was 0.22568435. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

MusclePharm's current Net Income (TTM) was -19.26. MusclePharm's current Cash Flow from Operations (TTM) was -11.72. ==> -11.72 > -19.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=0/11.0774
=0

Gearing (Last Year: Mar21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar20 to Mar21
=0.233/12.3648
=0.01884381

MusclePharm's gearing of this year was 0. MusclePharm's gearing of last year was 0.01884381. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar22)=Total Current Assets/Total Current Liabilities
=11.838/48.171
=0.24574952

Current Ratio (Last Year: Mar21)=Total Current Assets/Total Current Liabilities
=8.98/29.506
=0.30434488

MusclePharm's current ratio of this year was 0.24574952. MusclePharm's current ratio of last year was 0.30434488. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

MusclePharm's number of shares in issue this year was 33.386. MusclePharm's number of shares in issue last year was 45.493. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3.191/50.022
=0.06379193

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=18.489/61.33
=0.30146747

MusclePharm's gross margin of this year was 0.06379193. MusclePharm's gross margin of last year was 0.30146747. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar21)
=50.022/9.949
=5.02784199

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar20)
=61.33/14.795
=4.14531936

MusclePharm's asset turnover of this year was 5.02784199. MusclePharm's asset turnover of last year was 4.14531936. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MusclePharm has an F-score of 4 indicating the company's financial situation is typical for a stable company.

MusclePharm  (OTCPK:MSLPQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


MusclePharm Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of MusclePharm's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MusclePharm (MusclePharm) Business Description

Traded in Other Exchanges
N/A
Address
6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118
MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.
Executives
Eric Chin officer: Chief Accounting Officer 1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr director BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi officer: President & CFO 6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller director 4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc. 10 percent owner 1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc 10 percent owner C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney 10 percent owner 4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc 10 percent owner 265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell 10 percent owner 8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond director 10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123